A Comparison of Clinical Outcomes from Updated Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL)

被引：3

作者：

Palomba, M. Lia ^{[1
]}

Ghione, Paola ^{[2
,3
]}

Patel, Anik R. ^{[4
]}

Deighton, Kevin ^{[5
]}

Jacobson, Caron ^{[6
]}

Nahas, Myrna ^{[4
]}

Jung, A. Scott ^{[4
]}

Hatswell, Anthony J. ^{[5
]}

Kanters, Steve ^{[7
]}

Limbrick-Oldfield, Eve ^{[7
]}

Wade, Sally W. ^{[8
]}

Snider, Julia Thornton ^{[4
]}

Neelapu, Sattva S. ^{[9
]}

Riberio, Maria Teresa ^{[10
]}

Gribben, John ^{[11
]}

Radford, John ^{[12
]}

Bobillo, Sabela ^{[13
]}

Ghesquieres, Herve ^{[14
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, New York, NY USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, New York, NY USA

[3] Roswell Pk Comprehens Canc Ctr, Dept Med, Buffalo, NY USA

[4] Gilead Co, Kite, Santa Monica, CA USA

[5] Delta Hat, Nottingham, England

[6] Dana Farber Canc Ctr, Dept Med, Boston, MA USA

[7] RainCity Analyt, Vancouver, BC, Canada

[8] Wade Outcomes Res Consulting, Salt Lake City, UT USA

[9] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA

[10] Portuguese Oncol Inst Porto, Porto, Portugal

[11] Univ London, Barts Canc Inst, Barts & London Sch Med, Queen Mary, London, England

[12] Christie NHS Fdn Trust, Manchester Canc Res Ctr & Manchester Acad Hlth Sc, Manchester, Lancs, England

[13] Hebron Inst Oncol VHIO, Expt Hematol, Barcelona, Spain

[14] Univ Claude Bernard Lyon 1, Dept Hematol, Ctr Hosp Lyon Sud, Pierre Benite, France

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-147608

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3543

引用

页数：6

共 49 条

[21] A Retrospective Intra-Patient Analysis from ZUMA-5: Axicabtagene Ciloleucel (Axi-Cel) Compared with Prior Standard-of-Care Therapy in Patients with Relapsed/Refractory Follicular Lymphoma
Bachy, Emmanuel
Neelapu, Sattva S.
Chavez, Julio C.
Yakoub-Agha, Ibrahim
Lui, Christine
Wulff, Jacob
Miao, Harry
Nikolajeva, Olga
Best, Timothy
Linot, Camille
Jacobson, Caron A.
BLOOD, 2023, 142
[22] 3-Year Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/ Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
Neelapu, Sattva S.
Chavez, Julio
Sehgal, Alison R.
Epperla, Narendranath
Ulrickson, Matthew
Bachy, Emanuel
Munshi, Pashna N.
Casulo, Carla
Maloney, David G.
de Vos, Sven
Reshef, Ran
Leslie, Lori A.
Oluwole, Olalekan O.
Yakoub-Agha, Ibrahim
Khanal, Rashmi
Rosenblatt, Joseph D.
Yan, Jiali
Song, Qinghua
Peng, Weixin
Lui, Christine
Wulff, Jacob
Shen, Rhine R.
Poddar, Soumya
Miao, Harry
Beygi, Sara
Jacobson, Caron A.
BLOOD, 2022, 140 : 10380 - 10383
[23] ZUMA-22: A phase 3, randomized controlled study of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL).
Flinn, Ian W.
Jacobson, Caron Alyce
Nastoupil, Loretta J.
Morschhauser, Franck
Davies, Andrew
Buske, Christian
Corradini, Paolo
Guillermo, Armando Lopez
Reshef, Ran
Parameswaran, Vinod
Sehgal, Alison
Tees, Michael Timothy
Lui, Christine
Xue, Wei
Beygi, Sara
Grechko, Nikolay
Bolsue, Pisita
Giovanetti, Alessandro
To, Christina Ann
Nahas, Myrna
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[24] Long-Term Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non- Hodgkin Lymphoma (iNHL)
Neelapu, Sattva S.
Chavez, Julio C.
Sehgal, Alison R.
Epperla, Narendranath
Ulrickson, Matthew L.
Bachy, Emmanuel
Munshi, Pashna N.
Casulo, Carla
Maloney, David G.
de Vos, Sven
Reshef, Ran
Leslie, Lori A.
Oluwole, Olalekan O.
Yakoub-Agha, Ibrahim
Khanal, Rashmi
Rosenblatt, Joseph D.
Sherman, Marika
Dong, Jinghui
Giovanetti, Alessandro
Yang, Yin
Lui, Christine
Bashir, Zahid
Jung, A. Scott
Jacobson, Caron
BLOOD, 2021, 138
[25] Axicabtagene ciloleucel (axi-cel) product attributes and immune biomarkers associated with clinical outcomes in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) in ZUMA-5.
Plaks, Vicki
Chou, Justin
Goyal, Lovely
Zhang, Wangshu
Salunkhe, Shruti
Sehgal, Alison R.
Chavez, Julio C.
Neelapu, Sattva S.
Jacobson, Caron A.
Avanzi, Mauro P.
Rossi, John M.
Bot, Adrian
CANCER RESEARCH, 2021, 81 (13)
[26] Interim Analysis of ZUMA-5: a Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma.
Jacobson, Caron
Chavez, Julio
Sehgal, Alison
William, Basem
Munoz, Javier
Salles, Gilles
Casulo, Carla
Munshi, Pashna
Maloney, David
de Vos, Sven
Reshef, Ran
Leslie, Lori
Yakoub-Agha, Ibrahim
Oluwole, Olalekan
Fung, Henry Chi Hang
Plaks, Vicki
Yang, Yin
Lee, Jennifer
Avanzi, Mauro
Neelapu, Sattva
AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 : S20 - S21
[27] Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent NonHodgkin Lymphoma: 4-Year Follow-up from the Phase 2 ZUMA-5 Trial
Neelapu, Sattva S.
Chavez, Julio C.
Sehgal, Alison R.
Epperla, Narendranath
Ulrickson, Matthew L.
Bachy, Emmanuel
Munshi, Pashna N.
Casulo, Carla
Maloney, David G.
de Vos, Sven
Reshef, Ran
Leslie, Lori A.
Oluwole, Olalekan O.
Yakoub-Agha, Ibrahim
Khanal, Rashmi
Rosenblatt, Joseph D.
Peng, Weixin
Lui, Christine
Wulff, Jacob
Shen, Rhine R.
Poddar, Soumya
Lee, Andrew
Miao, Harry
Nikolajeva, Olga
Jacobson, Caron A.
BLOOD, 2023, 142
[28] A Comparison of One Year Outcomes in Patients With Refractory Large B Cell Lymphoma from ZUMA-1 (axicabtagene ciloleucel) and SCHOLAR-1
Gisselbrecht, C.
Locke, F. L.
Bartlett, N. L.
Lekakis, L. J.
Reagan, P. M.
Miklos, D. B.
Jacobson, C. A.
Braunschweig, I.
Oluwole, O. O.
Siddiqi, T.
Lin, Y.
Crump, M.
Kuruvilla, J.
Van den Neste, E.
Link, B. K.
Farooq, U.
Navale, L.
Go, W.
Wiezorek, J. S.
Neelapu, S. S.
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 72 - 73
[29] Clinical Outcomes with Prophylactic Corticosteroid Use for Axicabtagene Ciloleucel (axicel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/ R LBCL): A Multicenter Analysis
Vuyyala, Sowjanya
Corraes, Andre De Menezes Silva
Bailey, Megumi
Iqbal, Madiha
Munoz, Javier L.
Hunter, Bradley
Bansal, Radhika
Patel, Krish
Kharfan-Dabaja, Mohamed A.
Rosenthal, Allison C.
Wang, Yucai
Paludo, Jonas
Johnston, Patrick B.
Bennani, N. Nora
Villasboas, J. C. C.
Durani, Urshila
Ansell, Stephen M.
Lin, Yi
Khurana, Arushi
BLOOD, 2023, 142
[30] Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers
Sharp, John
Strati, Paolo
Bhatta, Subodh
Huang, Jennifer J.
Thomas, Colin
Reef, Daniel K.
Gorzewski, Alexander
Reinert, Catherine
Teferra, Andinet
Pelcovits, Ari
Ollila, Thomas
Maakaron, Joseph E.
Kamdar, Manali K.
Fitzgerald, Lindsey
Karmali, Reem
Grover, Natalie
Barta, Stefan K.
Voorhees, Timothy
Shadman, Mazyar
Ahmed, Sairah
Epperla, Narendranath
BLOOD, 2024, 144 : 2377 - 2378

← 1 2 3 4 5 →